Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) EBIT: €774 Mil (TTM As of Mar. 2026)

What is Shanghai Fosun Pharmaceutical (Group) Co EBIT?

Shanghai Fosun Pharmaceutical (Group) Co STU:08HH -2.38% 72 EBIT is €774 Mil as of Mar. 2026. GuruFocus rates STU:08HH with a GF Score™ of 72/100 and a GF Value™ of €2.12 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Shanghai Fosun Pharmaceutical (Group) Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €208 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €774 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai Fosun Pharmaceutical (Group) Co's annualized ROC % for the quarter that ended in Mar. 2026 was 2.35%. Shanghai Fosun Pharmaceutical (Group) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 23.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai Fosun Pharmaceutical (Group) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.59%.

Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai Fosun Pharmaceutical (Group) Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	411.076 * ( 1 - 20.47% )	/	( (13442.404	+	14351.295)	/ 2 )
=	326.9287428	/	13896.8495
=	2.35 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14556.748	-	1430.04	-	( 1862.196	-	max(0, 4416.51	-	4100.814	+	1862.196	))
=	13442.404

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15433.021	-	1410.054	-	( 1919.329	-	max(0, 4591.1	-	4262.772	+	1919.329	))
=	14351.295

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai Fosun Pharmaceutical (Group) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	830.376	/	( ( (2920.207 + max(475.836, 0))	+	(3048.595 + max(599.245, 0)) )	/	2 )
=	830.376	/	( ( 3396.043	+	3647.84 )	/	2 )
=	830.376	/	3521.9415
=	23.58 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1135.464	+	758.123	+	188.208)	-	(1430.04	+	0	+	175.919)
=	475.836

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1188.285	+	757.02	+	229.431)	-	(1410.054	+	0	+	165.437)
=	599.245

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai Fosun Pharmaceutical (Group) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	774.279	/	11750.013
	=	6.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co EBIT Related Terms

Shanghai Fosun Pharmaceutical (Group) Co EBIT Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's EBIT can be seen below:

Shanghai Fosun Pharmaceutical (Group) Co EBIT Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

953.91

749.90

589.41

734.70

773.26

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															213.99	204.57	172.24	189.88	207.59

STU:08HH vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT falls into.

Save Embed

72GF Score

Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €774 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €774 Mil mean?

Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) has a EBIT of €774 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Fosun Pharmaceutical (Group) Co.

Is Shanghai Fosun Pharmaceutical (Group) Co's EBIT too high?

Shanghai Fosun Pharmaceutical (Group) Co's current EBIT is €774 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Shanghai Fosun Pharmaceutical (Group) Co's EBIT compare to ZTS?

Shanghai Fosun Pharmaceutical (Group) Co's EBIT of €774 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai Fosun Pharmaceutical (Group) Co. Shanghai Fosun Pharmaceutical (Group) Co's current EBIT is €774 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.12, compared to a current price of €1.66 — trading 21.7% below its estimated fair value. The current EBIT is €774 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH), the current EBIT is €774 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of €1.66 is trading 21.7% below its estimated GF Value™ of €2.12. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.

Key valuation signals for STU:08HH:

EBIT: €774 Mil
GF Value™: €2.12 vs. price of €1.66 (21.7% below fair value)
GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the STU:08HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SZSE:000963 SZSE:000999 SZSE:002294 SHSE:600085 SZSE:000423 SZSE:000661 SHSE:600079 SHSE:600329 SZSE:002603 SHSE:688192 XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges SFOSF:USA 02196:Hong Kong 600196:China

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.

72GF Score

Get the complete analysis for STU:08HH

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.66

Price

€2.12

GF Value

View STU:08HH Analysis

See EBIT data for all stocks →